Multiple Sclerosis News Today Daily Digest

Posted by & filed under MS News.

Worth reading, the Ocrelizumab (Ocrevus) story, plus second and third items.  But a warning to all, not all the comments are positive.

Multiple Sclerosis News Today

The Web’s Daily Resource for Multiple Sclerosis News

In the 05/13/2019 edition:

Excerpts:MS News that Caught My Eye Last Week: Lemtrada Satisfaction, Limiting Tysabri’s PML Risk, MS and Pregnancy, Infusions Vs. Pills#AANAM – RRMS Patients Switching to Lemtrada Report Greater Satisfaction with Treatment and Improvements in Quality of Life I’m a self-proclaimed secondary progressive, rather than a remitting, multiple sclerosis (MS) person. But a year after round two of Lemtrada (alemtuzumab), I can agree with this report. Several of my symptoms are better, most notably my […]The post MS News that Caught My Eye Last Week: Lemtrada Satisfaction, Limiting Tysabri’s PML Risk, MS and Pregnancy, Infusions Vs. Pills appeared first on Multiple Sclerosis News Today.
Read on »

Ocrevus Approved in UK as First NHS Treatment for PPMSAfter first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now approved the use of Ocrevus (ocrelizumab) for people in the U.K. with early, inflammatory primary progressive multiple sclerosis (PPMS). This means that PPMS patients living in the U.K. will now have access to Ocrevus treatment through the […]The post Ocrevus Approved in UK as First NHS Treatment for PPMS appeared first on Multiple Sclerosis News Today.
Read on »

#AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data SuggestEarly, one-year data from the Phase 3 CHORDS study show that Ocrevus effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of Neurology (AAN) in the presentation, “One-year interim analysis results of the […]The post #AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest appeared first on Multiple Sclerosis News Today.
Read on »

#AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data ShowAubagio taken as 14 milligram (mg) tablet once daily significantly reduces the risk of relapse in people with relapsing multiple sclerosis (MS) over time irrespective of their prior treatment history, a pooled analysis of Phase 2 and Phase 3 trial results show. The findings were presented at the 2019 American Academy of Neurology (AAN) Annual Meeting, […]The post #AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data Show appeared first on Multiple Sclerosis News Today.
Read on »

I Survived a Marathon Comedy FestivalExactly one year ago on this day of writing, I was down and out. This year, I’m not exactly fighting fit, but the same set of circumstances has pushed me the distance. But it didn’t floor me. OK, OK, I’ll stop with the pugilistic metaphors — it’s not exactly knocking you out! Last year, I […]The post I Survived a Marathon Comedy Festival appeared first on Multiple Sclerosis News Today.
Read on »

#AANAM – Interferon Beta Exposure Does Not Seem to Increase Risk of Pregnancy Complications, Study SuggestsExposure to interferon beta does not seem to increase the risk of complications during pregnancy in women with multiple sclerosis (MS), new research suggests. The data were presented in an oral presentation, “Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS Preg study conducted in Finland and […]The post #AANAM – Interferon Beta Exposure Does Not Seem to Increase Risk of Pregnancy Complications, Study Suggests appeared first on Multiple Sclerosis News Today.
Read on »